Health Status Improvement with Ferric Carboxymaltose in Heart Failure with Reduced Ejection Fraction and Iron Deficiency

Aim Intravenous ferric carboxymaltose (FCM) has been shown to improve overall quality of life in iron-deficient heart failure with reduced ejection fraction (HFrEF) patients at a trial population level. This FAIR-HF and CONFIRM-HF pooled analysis explored the likelihood of individual improvement or...

Descripción completa

Detalles Bibliográficos
Autores: Butler, Javed, Khan, Muhammad Shahzeb, Friede, Tim, Jankowska, Ewa A., Fabien, Vincent, Goehring, Udo Michael, Dorigotti, Fabio, Metra, Marco, Piña, Ileana L., Coats, Andrew J. S., Rosano, Giuseppe, Comín Colet, Josep, Van Veldhuisen, Dirk J., Filippatos, Gerasimos S., Anker, Stefan D., Ponikowski, Piotr
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/187817
Acceso en línea:https://hdl.handle.net/2445/187817
Access Level:acceso abierto
Palabra clave:Insuficiència cardíaca
Dèficit de ferro
Ús terapèutic
Heart failure
Iron deficiency diseases
Therapeutic use
id ES_f3ecd820b537cde232d12e0155bc9e9f
oai_identifier_str oai:recercat.cat:2445/187817
network_acronym_str ES
network_name_str España
repository_id_str
spelling Health Status Improvement with Ferric Carboxymaltose in Heart Failure with Reduced Ejection Fraction and Iron DeficiencyButler, JavedKhan, Muhammad ShahzebFriede, TimJankowska, Ewa A.Fabien, VincentGoehring, Udo MichaelDorigotti, FabioMetra, MarcoPiña, Ileana L.Coats, Andrew J. S.Rosano, GiuseppeComín Colet, JosepVan Veldhuisen, Dirk J.Filippatos, Gerasimos S.Anker, Stefan D.Ponikowski, PiotrInsuficiència cardíacaDèficit de ferroÚs terapèuticHeart failureIron deficiency diseasesTherapeutic useAim Intravenous ferric carboxymaltose (FCM) has been shown to improve overall quality of life in iron-deficient heart failure with reduced ejection fraction (HFrEF) patients at a trial population level. This FAIR-HF and CONFIRM-HF pooled analysis explored the likelihood of individual improvement or deterioration in Kansas City Cardiomyopathy Questionnaire (KCCQ) domains with FCM versus placebo and evaluated the stability of this response over time. Methods and results Changes versus baseline in KCCQ overall summary score (OSS), clinical summary score (CSS) and total symptom score (TSS) were assessed at weeks 12 and 24 in FCM and placebo groups. Mean between-group differences were estimated and individual responder analyses and analyses of response stability were performed. Overall, 760 (FCM, n = 454) patients were studied. At week 12, the mean improvement in KCCQ OSS was 10.6 points with FCM versus 4.8 points with placebo (least-square mean difference [95% confidence interval, CI] 4.36 [2.14; 6.59] points). A higher proportion of patients on FCM versus placebo experienced a KCCQ OSS improvement of >= 5 (58.3% vs. 43.5%; odds ratio [95% CI] 1.81 [1.30; 2.51]), >= 10 (42.4% vs. 29.3%; 1.73 [1.23; 2.43]) or >= 15 (32.1% vs. 22.6%; 1.46 [1.02; 2.11]) points. Differences were similar at week 24 and for CSS and TSS domains. Of FCM patients with a >= 5-, >= 10- or >= 15-point improvement in KCCQ OSS at week 12, >75% sustained this improvement at week 24. Conclusion Treatment of iron-deficient HFrEF patients with intravenous FCM conveyed clinically relevant improvements in health status at an individual-patient level; benefits were sustained over time in most patients.Wiley2022202220222022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion12 p.application/pdfhttps://hdl.handle.net/2445/187817Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.1002/ejhf.2478European Journal of Heart Failure, 2022, vol. 24, num. 5, p. 821-832https://doi.org/10.1002/ejhf.2478cc by-nc-nd (c) Butler, Javed et al., 2022http://creativecommons.org/licenses/by-nc-nd/3.0/es/info:eu-repo/semantics/openAccessoai:recercat.cat:2445/1878172026-05-29T05:05:01Z
dc.title.none.fl_str_mv Health Status Improvement with Ferric Carboxymaltose in Heart Failure with Reduced Ejection Fraction and Iron Deficiency
title Health Status Improvement with Ferric Carboxymaltose in Heart Failure with Reduced Ejection Fraction and Iron Deficiency
spellingShingle Health Status Improvement with Ferric Carboxymaltose in Heart Failure with Reduced Ejection Fraction and Iron Deficiency
Butler, Javed
Insuficiència cardíaca
Dèficit de ferro
Ús terapèutic
Heart failure
Iron deficiency diseases
Therapeutic use
title_short Health Status Improvement with Ferric Carboxymaltose in Heart Failure with Reduced Ejection Fraction and Iron Deficiency
title_full Health Status Improvement with Ferric Carboxymaltose in Heart Failure with Reduced Ejection Fraction and Iron Deficiency
title_fullStr Health Status Improvement with Ferric Carboxymaltose in Heart Failure with Reduced Ejection Fraction and Iron Deficiency
title_full_unstemmed Health Status Improvement with Ferric Carboxymaltose in Heart Failure with Reduced Ejection Fraction and Iron Deficiency
title_sort Health Status Improvement with Ferric Carboxymaltose in Heart Failure with Reduced Ejection Fraction and Iron Deficiency
dc.creator.none.fl_str_mv Butler, Javed
Khan, Muhammad Shahzeb
Friede, Tim
Jankowska, Ewa A.
Fabien, Vincent
Goehring, Udo Michael
Dorigotti, Fabio
Metra, Marco
Piña, Ileana L.
Coats, Andrew J. S.
Rosano, Giuseppe
Comín Colet, Josep
Van Veldhuisen, Dirk J.
Filippatos, Gerasimos S.
Anker, Stefan D.
Ponikowski, Piotr
author Butler, Javed
author_facet Butler, Javed
Khan, Muhammad Shahzeb
Friede, Tim
Jankowska, Ewa A.
Fabien, Vincent
Goehring, Udo Michael
Dorigotti, Fabio
Metra, Marco
Piña, Ileana L.
Coats, Andrew J. S.
Rosano, Giuseppe
Comín Colet, Josep
Van Veldhuisen, Dirk J.
Filippatos, Gerasimos S.
Anker, Stefan D.
Ponikowski, Piotr
author_role author
author2 Khan, Muhammad Shahzeb
Friede, Tim
Jankowska, Ewa A.
Fabien, Vincent
Goehring, Udo Michael
Dorigotti, Fabio
Metra, Marco
Piña, Ileana L.
Coats, Andrew J. S.
Rosano, Giuseppe
Comín Colet, Josep
Van Veldhuisen, Dirk J.
Filippatos, Gerasimos S.
Anker, Stefan D.
Ponikowski, Piotr
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Insuficiència cardíaca
Dèficit de ferro
Ús terapèutic
Heart failure
Iron deficiency diseases
Therapeutic use
topic Insuficiència cardíaca
Dèficit de ferro
Ús terapèutic
Heart failure
Iron deficiency diseases
Therapeutic use
description Aim Intravenous ferric carboxymaltose (FCM) has been shown to improve overall quality of life in iron-deficient heart failure with reduced ejection fraction (HFrEF) patients at a trial population level. This FAIR-HF and CONFIRM-HF pooled analysis explored the likelihood of individual improvement or deterioration in Kansas City Cardiomyopathy Questionnaire (KCCQ) domains with FCM versus placebo and evaluated the stability of this response over time. Methods and results Changes versus baseline in KCCQ overall summary score (OSS), clinical summary score (CSS) and total symptom score (TSS) were assessed at weeks 12 and 24 in FCM and placebo groups. Mean between-group differences were estimated and individual responder analyses and analyses of response stability were performed. Overall, 760 (FCM, n = 454) patients were studied. At week 12, the mean improvement in KCCQ OSS was 10.6 points with FCM versus 4.8 points with placebo (least-square mean difference [95% confidence interval, CI] 4.36 [2.14; 6.59] points). A higher proportion of patients on FCM versus placebo experienced a KCCQ OSS improvement of >= 5 (58.3% vs. 43.5%; odds ratio [95% CI] 1.81 [1.30; 2.51]), >= 10 (42.4% vs. 29.3%; 1.73 [1.23; 2.43]) or >= 15 (32.1% vs. 22.6%; 1.46 [1.02; 2.11]) points. Differences were similar at week 24 and for CSS and TSS domains. Of FCM patients with a >= 5-, >= 10- or >= 15-point improvement in KCCQ OSS at week 12, >75% sustained this improvement at week 24. Conclusion Treatment of iron-deficient HFrEF patients with intravenous FCM conveyed clinically relevant improvements in health status at an individual-patient level; benefits were sustained over time in most patients.
publishDate 2022
dc.date.none.fl_str_mv 2022
2022
2022
2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/187817
url https://hdl.handle.net/2445/187817
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1002/ejhf.2478
European Journal of Heart Failure, 2022, vol. 24, num. 5, p. 821-832
https://doi.org/10.1002/ejhf.2478
dc.rights.none.fl_str_mv cc by-nc-nd (c) Butler, Javed et al., 2022
http://creativecommons.org/licenses/by-nc-nd/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc by-nc-nd (c) Butler, Javed et al., 2022
http://creativecommons.org/licenses/by-nc-nd/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 12 p.
application/pdf
dc.publisher.none.fl_str_mv Wiley
publisher.none.fl_str_mv Wiley
dc.source.none.fl_str_mv Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869424423294992384
score 15,811543

Similares en LA Referencia